Subheading Mentari Therapeutics has chosen a reverse‑merger approach to prepare for a public listing. A reverse merger involves merging with an already‑public company to gain rapid market access, which is attractive to bio‑startups that urgently need capital and visibility. This decision reflects a strategic judgment to accelerate growth as a spin‑out derived from the hub‑spoke model known as Paragon. Mentari holds two migraine therapeutic candidates and targets patients whose symptoms are insufficiently controlled by existing drugs. The migraine treatment market still exhibits heterogeneous response rates and low patient satisfaction, leaving substantial entry opportunities. The company’s intent to explore novel mechanisms and deliver differentiated treatment options is evident. Paragon’s hub‑spoke bio model rapidly spins out innovative ideas into independent companies, providing early‑stage research teams with autonomy and creating an environment that readily attracts investors. Mentari’s choice to become an independent entity through a reverse merger can be viewed as a successful application of this model. Capital raised from the listing will directly support accelerated clinical development and market entry strategies. From an investor perspective, the risk and growth potential of early‑stage biotech firms must be evaluated concurrently, while patients and clinicians can anticipate new therapeutic options. Across the broader biotech industry, this trend suggests an expanding wave of rapid listings for spin‑out companies.